Scholarlink

Abstract <p>The therapeutic landscape of metastatic triple-negative breast cancer (mTNBC) has evolved with the development of antibody–drug conjugates (ADCs), which enable the targeting of novel surface antigens to deliver potent cytotoxic chemotherapy payloads.</p> Purpose of the Review <p>This review outlines the current standard of care and highlights recent pivotal trials supporting trop-2 ADCs as frontline therapy.</p> Recent Findings <p>The treatment of mTNBC has shifted from chemotherapy-based to a biomarker-informed paradigm. In parallel, key biological features of mTNBC – genomic instability, increased tumor-infiltrating lymphocytes, and defects in DNA damage repair – have created opportunities for targeted and immune-based treatment strategies. We examine the potential of novel biomarkers and investigational therapeutic methods that might further advance the treatment of mTNBC.</p> Summary <p>This review discusses how optimizing ADC sequencing, identifying predictive biomarkers, and overcoming therapeutic resistance are critical ongoing research areas to advance therapeutic options for mTNBC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evolving Frontiers in Metastatic Triple-Negative Breast Cancer: Therapeutic Strategies and Emerging Paradigms

  • 期刊论文

  • 发表日期：

    2026年6月23日

查看全文
  • Luiza Doro Pereira,
  • Shipra Gandhi,
  • Manali Bhave

摘要

Abstract

The therapeutic landscape of metastatic triple-negative breast cancer (mTNBC) has evolved with the development of antibody–drug conjugates (ADCs), which enable the targeting of novel surface antigens to deliver potent cytotoxic chemotherapy payloads.

Purpose of the Review

This review outlines the current standard of care and highlights recent pivotal trials supporting trop-2 ADCs as frontline therapy.

Recent Findings

The treatment of mTNBC has shifted from chemotherapy-based to a biomarker-informed paradigm. In parallel, key biological features of mTNBC – genomic instability, increased tumor-infiltrating lymphocytes, and defects in DNA damage repair – have created opportunities for targeted and immune-based treatment strategies. We examine the potential of novel biomarkers and investigational therapeutic methods that might further advance the treatment of mTNBC.

Summary

This review discusses how optimizing ADC sequencing, identifying predictive biomarkers, and overcoming therapeutic resistance are critical ongoing research areas to advance therapeutic options for mTNBC.